ProCE Banner Activity

Phase II ELARA: 3-Year Follow-up of Tisagenlecleucel in R/R Follicular Lymphoma

Conference Coverage

In this extended follow-up of the phase II ELARA trial, tisagenlecleucel was associated with durable responses in patients with relapsed/refractory follicular lymphoma, with median duration of response, time to next treatment, and overall survival not reached.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.